Alpha Cognition Inc. (ACOG)

Market Cap	141.97M +65.0%
Revenue (ttm)	10.22M
Net Income	-20.67M
EPS	-1.18
Shares Out	21.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,519
Open	7.02
Previous Close	6.96
Day's Range	6.51 - 7.55
52-Week Range	3.75 - 11.54
Beta	2.52
Analysts	Strong Buy
Price Target	18.00 (+176.07%)
Earnings Date	May 14, 2026

About ACOG

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the trea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: Canada
• Stock Exchange: NASDAQ
• Ticker Symbol: ACOG
• Website: https://www.alphacognition.com

Analyst Summary

According to one analyst, the rating for ACOG stock is "Strong Buy" and the 12-month stock price target is $18.0.

Price Target

$18.0

(176.07% upside)

Analyst Consensus: Strong Buy